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Cigarette smokingisoneofthemajorcausesofcarcinogenesis.Direct genotoxicityinduced bycigarette smokeleadstoinitiationof
carcinogenesis. Nongenotoxic (epigenetic) eﬀects of cigarette smoke also act as modulators altering cellular functions. These two
eﬀects underlie the mechanisms of tumor promotion and progression. While there is no lack of general reviews on the genotoxic
and carcinogenic potentials of cigarette smoke in lung carcinogenesis, updated review on the epigenetic eﬀects and molecular
mechanisms of cigarette smoke and carcinogenesis, not limited to lung, is lacking. We are presenting a comprehensive review
of recent investigations on cigarette smoke, with special attentions to nicotine, NNK, and PAHs. The current understanding on
their molecular mechanisms include (1) receptors, (2) cell cycle regulators, (3) signaling pathways, (4) apoptosis mediators, (5)
angiogenic factors, and (6) invasive and metastasis mediators. This review highlighted the complexity biological responses to
cigarette smoke components and their involvements in tumorigenesis.
1.Introduction
It is known that 90–95% of all cancers are caused by or
closely associated with environmental factors and lifestyle.
This includes diet (30–35%), cigarette smoking (25–30%),
and alcohol consumption (4–6%) [1]. Cigarette smoking is
animportantriskfactorforheartdisease,chronicobstructive
pulmonary disease, stroke, and acute respiratory diseases.
In addition to all these noncancer diseases, it is also highly
associated with human cancer development. The Interna-
tional Agency for Research on Cancer (IARC) identiﬁed
cigarette smoking as the cause of cancer in more organ
sites than any other human carcinogens. These include
cancers of the lungs, oral cavity, larynx, nasal cavity,
esophagus, stomach, pancreas, liver, kidney, urinary bladder,
uterine cervix, and bone marrow [2]. There are over
5000 chemical compounds identiﬁed in tobacco and 62
of these have been evaluated by IARC as showing “suﬃ-
cient evidence for carcinogenicity” in either animals or in
humans [2, 3]. The major carcinogenic compounds include,
but not limited to, radioactive polonium, N-nitrosamines
such as 4-(methylnitrosaminao)-1-(3-pyridyl)-1-butanone
(NNK), polycyclic aromatic hydrocarbons (PAHs) (e.g.,
benzo[a]pyrene (BaP)), and benzene [4]. A ﬁne review on
this aspect has been presented by Hecht in 2006 [5].
The carcinogenesis process is complex. Multistep pro-
cesses of genetic and molecular defects have taken place
before the manifestation of cancer [6]. Traditionally, there
are three basic stages of carcinogenesis: initiation, promo-
tion, and progression [7]. Carcinogenesis process is usually2 Journal of Oncology
accompanied by changes in structure and function of central
genomic information coded in the DNA leading to various
oncogene activations and tumor suppressor gene inactiva-
tions [8]. In addition, multiple signaling pathways may also
be deregulated during the process of cancer development.
Cancer growth also requires molecular changes that either
aﬀect the tumor cells themselves or alter the interaction
between tumor cells and their surrounding stromal environ-
ment or the immune system. These events may eventually
lead to tumor growth, invasion, and metastasis.
Cigarette smoke components have been reported to pro-
mote tumorigenesis by several mechanisms involving all
three stages of carcinogenesis [5]. Genotoxic agents in
cigarette smoke induce DNA damage through several mech-
anisms including gene point mutation, deletions, insertions,
recombinations, rearrangements, and chromosomal aberra-
tions. PAHs and nitrosamines are two of the most abundant
genotoxic components in cigarette smoke. In addition to
genotoxic eﬀects, nongenotoxic eﬀectsof cigarette smoke are
also extremely important. These eﬀects can also act as mod-
ulators which alter cellular functions including cell prolifer-
ation and cell death. While synergistic eﬀects of genotoxic
carcinogens are known to occur, interaction between non-
genotoxic (epigenetic) factors and genotoxic agents may also
synergistically increase the risk for carcinogenesis [9]. The
genotoxicity leading to carcinogenesis has been extensively
reviewed in recent years [9–11]. In this present review, aside
from a brief overview on the genotoxic eﬀects of cigarette
smoke components, we will provide a more extensive review
on the non-genotoxic mechanisms of carcinogenesis by
cigarette smoke or its components.
2.The Three CarcinogensisStepsAffectedby
CigaretteSmoke
Step 1 (Initiation of Carcinogenesis). Carcinogenesis may be
the result of chemical or biological insults to normal cells
through multistep processes that involves genomic changes
(initiation of cancer development). Such changes eventually
may also lead to cancer promotion and progression [12].
Some of the cigarette smoke components can act directly on
DNA,butmany require enzyme conversionbefore becoming
carcinogenic [10, 11]. Most of such “conversions” involve
metabolic changes via cytochrome p450s (P450s) such as
P450s 1A2, 2A13, 2E1, and 3A4 to form the electrophilic
entities that can bind to DNA to form DNA adducts. Such
adduct formation is usually at the adenine or guanine sites
of the DNA and lead to mutations such as those observed
in the KRAS oncogene in lung cancer or those in the TP53
genein a variety of cigarette smoke-induced cancers [13, 14].
These mutation represent the so-called initiation step of
carcinogenesis [15].
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK) and N-nitrosonornicotine (NNN) are the most
potent tobacco-speciﬁc nitrosamines in tobacco products
and cigarette smoke. These compounds are formed from
tobacco alkaloids like nicotine during the curing process
of tobacco and are important tobacco carcinogens that can
aﬀectdiﬀerenttissuesdependingonthespeciﬁcnitrosamines
or their metabolites involved [5, 10]. NNK is a potent lung
carcinogen but can also induce liver and nasal cancers. NNN
has been shown to be carcinogenic to esophagus, nasal
cavity, and respiratory tract in laboratory animals [16]. In
humans, metabolites derived from NNK and the metabolites
of NNK can also be identiﬁed in the smoker’s urine
[17].
Benzo[a]pyrene (BaP), one of the PAHs, is classiﬁed as
a Group 1 carcinogen to humans [3]. It has been shown to
have strong association and tumor-induction potentials in
lungs, trachea, and mammary glands [5]. The carcinogenic
potency of BaP has been demonstrated to be related to
its metabolites which form DNA adducts with site-speciﬁc
hotspot mutation in the p53 tumor suppressor gene. Positive
correlations of such adduct formation and tumor are indeed
found in the lung cancer tissues of cigarette smokers [18].
These ﬁndings indicate that DNA mutations are
increased in both tumor and nontumor bearing tissues of
smokers. However, it must be pointed out that DNA adduct
formations induced by cigarette smoke still cannot fully rep-
resent all the risk factors for cancer development in cigarette
smokers [19]. For example, while there is higher incidence
of pancreatic cancer in cigarette smokers than nonsmokers
[20].Assays forNNKmetabolites inpancreatic cancertissues
inhumans showednosigniﬁcant diﬀerencebetweensmokers
and nonsmokers [21]. Thus, it is apparent that NNK-
inducedDNAadductsalonearenotsolelyresponsible forthe
pancreatic cancers in cigarette smokers. Nevertheless, NNK
and its metabolite, NNAL (4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol), are the only environmental carcinogens
known to induce pancreatic cancer in animal models [22].
Thus, the contribution of NNK to pancreatic cancer in
c i g a r e t t es m o k e r ss t i l lc a n n o tb ei g n o r e d .F u r t h e r m o r e ,i t
is suggested that, in addition to DNA damage, synergistic
interactions between DNA reactivity and epigenetic actions
such as increased cell proliferation induced by NNK or
by other chemicals in cigarette smoke may be needed for
actual cancer development in such patients [23, 24]. There is
indication that cigarette smoke carcinogens or cocarcinogen,
suchas nicotine,mayalso playadirect roletoenhancecancer
promotion and progression in human cancers after cancer
development [25]. Such genotoxic mechanisms for cancer
initiation and carcinogenesis bycigarette smoke components
are well covered and discussed in several excellent reviews [5,
10,11,26–28].Readersareencouragedreferring tothem.For
the remaining portion of this article, we will provide more
information on the non-genotoxic (epigenetic) mechanisms
involved in cancer promotion and progression via cigarette
smoke.
Step 2 (Cancer Promotion). Cancer promotion is character-
ized by deregulation of signaling pathways which control
cell proliferation, apoptosis, and so forth, [29]. It is believed
that although there are various genetic pathways which
may lead to cancer development or cancer behaviors, there
are certain hallmark capabilities or mechanisms which
are commonly shared by all tumors. In the following
discussion, we will describe each mechanism with illustrated
examples.Journal of Oncology 3
2.1. Eﬀects of Cigarette Smoke on Self-Suﬃciency in Growth
Signals. Normal cells need mitogenic growth signals to
induce proliferation. These signals are transmitted into cells
by receptors that bind distinct signaling molecules. In cancer
cells, the receptors which transduce growth signals into cells
are targets of deregulation during tumorigenesis. Recep-
tor overexpression allows cancer cells to become hyper-
responsive to low levels of growth factors that generally are
not suﬃcient to trigger proliferation in normal cells [29].
Nicotine,a major componentofcigarette smoke,is known to
be a chemical that plays an important role in carcinogenesis
in cigarette smokers [30]. Nicotine behaves like those
growth factors which exert their biological functions mainly
through the nicotinic acetylcholine receptors (nAChR) [31],
β-adrenoceptors (β-AR) [32] or epidermal growth factor
receptor (EGFR) [33]. The functions of these receptors are
cell-type speciﬁc and the expression level and receptor sen-
sitivity can be modiﬁed by nicotine. Obviously, alterations
in either the receptor expressions or sensitivity play an
important role in cigarette smoke-induced carcinogenesis
[34–36].
RecentstudybyLeeetal.reportedthatα9nA ChRe xpr es -
sion in human breast tumors is elevated in advanced stages
of breast cancer and plays important roles in human breast
carcinogenesis [37]. Nicotine has been shown to mediate
α9 nAChR signaling and upregulate cyclin D3 expression in
breastcanercellsandbreastcancertissues[38].Furthermore,
it is also found that activation of the expression ofα9n A C h R
by nicotine is through AKT signaling [39] and activation
of α9 nAChR signaling would elevate the phosphorylation
status of adhesion molecule which plays a role in cancer
metastasis [40]. Proliferation of mesothelioma cells is also
f o u n dt ob ee n h a n c e db yn i c o t i n e[ 41]. This enhancement
has been shown to be via α7 nAChR with activation of
ERK1/2cascadeas well asinductionofNF-κBan dBadphos -
phorylation. All these events eventually lead to inhibition of
apoptosis [41] and increase of cancer risk. These ﬁndings
were further supported by Wada et al. [42]w h oo b s e r v e d
that nicotine promoted cell proliferation via α7n A C h R
mediated p44/p42-MAPK activation. Moreover, in our own
study, we also reported that nicotine inducedhuman bladder
cells proliferation through ERK1/2 and Stat3 signaling
downstream ofα7n A C h Ra n dβ-adrenoceptors (β-AR)[43].
In sum, all these studies indicate that nicotine, an important
ingredientofcigarettesmoke,promotescellularproliferation
which plays a critical role in carcinogenesis.
Other than nicotine, nitrosamines, such as NNK and
NNN, also induced cancer cells growth through nAChR.
NNKinducedcarcinogenesisbybindingtonAChRespecially
for α7 nAChR, whereas the biological impact of NNN is
mainly modulated by α4/β2n A C h R[ 8, 44–46]. It has been
demonstrated that nicotine or NNK stimulated lung cancer
cell proliferation via α7 nAChR with activations of PKC,
R A F 1 ,A K T ,E R K 1 / 2 ,a n dt r a n s c r i p t i o nf a c t o r ss u c ha sJ U N ,
FOS, and MYC [47–49]. Question has been raised concern-
ing the possibility that speciﬁc nAChR subunit upregulated
by nicotine or NNK may be tissue speciﬁc or dependent.
For instance, with nicotine or NNK, α7n A C h Ri st h e
primary nAChR subunit which mediates tumorigenesis in
lungs giving rise to pulmonary squamous cell carcinoma and
mesothelioma [36]. On the other hand, α9n A C h Ri sm o r e
associated with breast cancer [37]. Thus, the speciﬁc types of
nAChR expressed in cancer cells may be considered as useful
molecular targets for potential clinical therapy [50]. How-
ever, most of the nAChR present in cancer cells are still not
functionally characterized yet. Future study will be needed
to understand the functions of diﬀerent nAChR subtype in
cancer cells and the downstream signal pathways involved in
tumorigenesis.
Inadditionto nAChR,anumber ofstudiesindicatedthat
nicotine and NNK might also exert their biological activities
through activation of receptors such as β-adrenoceptors (β-
A R ) ,E G F R ,o ri n s u l i n - l i k eg r o w t hf a c t o rr e c e p t o r( I G F R )
or transactivation by nAChR signaling. It has been demon-
strated that β- ARa cti va ti onpr om ot esth egr o wth sofva ri ous
adenocarcinoma. For example, NNK can stimulate HT-29
cell proliferation through β-AR followed by cyclin AMP
elevation and COX-2 expression [51]. Consistently, NNK
stimulates thegrowthof pulmonary adenocarcinoma in vitro
and in vivo via the release of arachidonic acid through COX-
2 and 5-lipoxygenase (5-LOX) pathways that are mainly
regulated by β-AR [52]. In another study by Schuller and
Cekanova, NNK is reported to stimulate β2-AR receptor
pathway (including PKA, cAMP, CREB) and transactivate
EGFR pathway (such as Raf-1/ERK1/2 signaling) in the
development of lung cancer [53]. It has also been reported
that antagonists of β-AR can inhibit the development of
NNK-induced lung adenocarcinoma [52]. Such antagonists
are also found to be eﬀective in reducing the stimulatory
eﬀects of nicotine on PKC, ERK1/2 activations, COX-
2 expression, and gastric cancer cell proliferation [54].
Elevation of noradrenaline by nicotine via α7 nAChR up-
regulation leading to signiﬁcantly enhanced growth and
angiogenesis in both gastric cancer and colon cancer has
also been demonstrated [55]. Various investigators have
also shown increases in neurotransmitters lead to β-AR
activation, transactivation of EGFR, and the release of EGF
[32, 54, 56]. Thus, an interrelationship between nAChR and
neurotransmitter is apparent. Indeed, our recent investi-
gation provided compelling evidence that chronic nicotine
exposure induced release of noradrenaline via α4/β2n A C h R
activation followed by β-AR transactivation. Our study
further demonstrated that blocking of β-AR with antago-
nist reversed the nicotine-induced cellular proliferative and
chemoresistance [57].
Al-Wadei et al. ﬁrst reported that nicotine contributes
to the development of smoking-related pancreatic ductal
adenocarcinoma(PDAC)withelevatedlevelsofstress neuro-
transmitters (adrenaline and noradrenaline) and induction
of cAMP, pCREB, and pERK1/2, and inhibition of γ-ami-
nobutyric acid (GABA) [58]. GABA has been reported
to possess tumor suppressor function suppressing both
β-AR stimulated PDAC growth and migration in vitro
[59]. However, while GABA is suppressed in PDACs, nora-
drenaline, PKA, p-CREB, and pERK1/2 in these tissues are
overexpressed. A reduction of GABA by NNK is observed in
lung adenocarcinoma [60]. These authors suggested that
nicotine and NNK may contribute to the development of4 Journal of Oncology
PDAC insmokersby suppression ofGABA with inductionof
stress neurotransmitters [61].Schulleretal.furtherproposed
that nicotine induces the release of stress neurotransmitters
through activation of α7 nAChR and inhibits release of
GABAvia inhibition of α4/β2n A C h R[ 61]. Itisnow believed
that the stress neurotransmitter released via nAChR activa-
tion plays an important role in smoking-associated tumori-
genesis [62]. However, the precise mechanisms involved in
the regulation and the function of neurotransmitter released
by nicotine and NNK are still uncertain. Future research on
this area is encouraged.
It has also been shown that NNK can promote β-
AR-mediated transactivation of EGFR followed by ERK1/2
phosphorylation leading to an increased proliferation in
pancreatic cancer cells [63]. NNK is also reported to induce
endogenous IGFR which is associated with the development
of lung tumors [64]. Huang et al. also indicated that both
activation ofthromboxane A2(TxA2)receptorand synthesis
ofTxA2playcriticalroles inNNK-promotedlungcancercell
proliferation. TxA2 activates the transcriptional factor CREB
through both ERK and PI3K/AKT pathways, which may
also lead to PCNA and Bcl-2 overexpressions and cell pro-
liferation [65]. These studies provide valuable information
on the mechanisms which involve in proliferative signaling
stimulated by nicotine and NNK through activation of
nAChR, β-AR and other growth factor receptors in cancer
cells. Triggering such receptors by cigarette smoke would
further lead to rapid cell proliferation, cellular migration,
invasion, and metastasis. In short, these investigations on
the nAChR, and nAChR transactivated with other receptors
represent the pivotal role in regulating multiple cellular
cascades in general cell functions and in carcinogenesis.
Nicotine is also known to inﬂuence signal transduc-
ers and activators of transcription 3 (Stat 3) which is
an important signal transducer mediating signaling by
numerous cytokines, growth factors, and oncoproteins [66].
Findings from our own laboratories indicate that nico-
tine induces bladder cancer cells proliferation through α7
nAChR, α4β2n A C h R ,a n dβ-AR followed by activation of
ERK1/2 and Stat 3 [43]. Stat3 signaling further enhanced
NF-κB activation, cyclin D1 overexpression, and cell cycle
progression [43]. Moreover, we also revealed that prolonged
stimulation by nicotine upregulated α4/β2n A C h Ra n dβ-
AR followed with activation of Stat 3 leading to signiﬁcant
increase in chemoresistance in cells from bladder cancers
[57].
In recent years, nongenotoxic actions of PAHs have
gained increasing attentions. The biological eﬀects of PAHs
are mainly mediated via aryl hydrocarbone receptor (AhR).
Through AhR, PAHs can then trigger ERK1/2 activation and
signaling in hepatic “stem cell-like” epithelial cells [67, 68].
Other PAHs, such as benz(a)anthracene (BaA), has also
been found to increase DNA synthesis and promote G1-S
progression in serum deprived MCF-7 cells [69]. BaP has
been shown to increase incidence of tumors in estrogen-
responsive rodents, suggesting that it may also aﬀect ER-
mediated signaling [70]. PAHs can have actions which
mimic those of estrogen. Some investigators believed that
the estrogenic property of PAHs may be responsible for
the induction of cell proliferation. BaP and BaA have been
reported to act as estrogens that stimulate and initiate the
ER-mediated transcription and cell cycle progression and
enhanceERαphosphorylation[70].Ontheotherhand,there
is also indication that the estradiol-dependent cell growth of
MCF-7 cells can be inhibited by BaP and BaA [71, 72]. Thus,
the actions of PAHs on estrogen-dependent cell proliferation
are still controversial. Further studies are needed to elucidate
more on the roles of PAHs in carcinogenicity.
2.2. Eﬀects of Cigarette Smoke on Antigrowth Signals. In nor-
mal tissues, the antigrowth signals operate to maintain cel-
lular quiescence and tissue homeostasis. Antigrowth signals
can block proliferation by forcing the cell cycle progression
into the quiescent (G0) state. The cell cycle transition from
G1 to S phase is the key regulatory step in the cell cycle and
is mainly regulated by CDK4/6-cyclin D and CDK2-cyclin
E complexes. These complexes induce Rb phosphorylation
and liberate E2Fs allowing cell proliferation to occur [73].
Disruption of the Rb pathway would therefore render cells
insensitive to antigrowth factors [29]. Nicotine has been
reported to induce binding of Raf-1 to Rb with activation
of cyclins and CDKs as well as inactivation of Rb [74]. Via
activations of nAChR and β-AR, nicotine and NNK both
exhibit mitogenic properties by inducing cyclin D1 overex-
pression leading to G1/S transition and increasing cell cycle
progression [49, 75, 76]. NNK can also stimulate normal
human lung epithelial cells proliferation through NF-κBa n d
cyclin D1 upregulation in an ERK1/2-dependent pathway
[75]. In our own laboratory, we have also demonstrated that
nicotine-induced cyclin D1 overexpression is regulated via
Stat3, ERK1/2, and NF-κB-dependent pathways in bladder
cancer cells [43].
Other study also shows that PI3K/AKT-dependent cellu-
lar proliferation is also enhanced in response to NNK [49].
The PI3K/AKT pathway is critical in cancer cells because
it inﬂuences tumorigenesis, tumor growth, and therapeutic
resistance [77]. The PI3K/AKT activation is documented in
both NNK-treated A/J mice and in human lung cancers
from smokers [48]. It also plays a role in NNK-induced
cell transformation, proliferation, and metastasis [48]. It
has been suggested that AKT and NF-κBm a ys e r v ea sk e y
targets for nicotine or NNK stimulation in the development
of lung cancer [49]. West et al. also reported that BEAS2B
cells treated with NNK for eight-week period increased
cellular proliferation through activation of PI3K/AKT path-
ways [48]. However, PI3K/AKT activation does not always
occur in all cancer cells induced by nicotine. Our previous
study indicates that nicotine induced bladder cancer cell
proliferation through Stat3 and ERK1/2 signalings instead
of via AKT pathway [43]. All these investigations suggest
that nicotine or NNK can activate ERK1/2, Stat3, or AKT
signaling to interrupt the antigrowth signals leading to
enhanced cell cycle progression and cancer promotion. It is
important to remember that cigarette smoke components
other than nicotine or NNK may also impede on anti-
growth mechanisms enhancing cancer development and
promotion. Such area of research also deserves focus in the
future.Journal of Oncology 5
2.3. Antiapoptotic Eﬀects of Cigarette Smoke. Apoptosis plays
an important role in controlling normal development,
homeostasis, and immune defense via elimination of redun-
dant or abnormal cells in the organism [78]. Failure in cell
elimination (reduction of apoptosis) may lead to undesir-
able cell survival and unchecked cell growths. Resistance
to apoptosis is often seen in cancers where cancer cells
tend to lose their proapoptotic potentials because of gene
mutations. The most important gene mutations include
tumor suppressor genes such as p53. Nicotine has been
shown to inhibit apoptosis induced by tumor necrosis factor
(TNF), by ultraviolet (UV), radiation, or by chemothera-
peutic drugs such as cisplatin, vinblastine, paclitaxel, and
doxorubicin [79]. This antiapoptotic action has been shown
to be via PI3K/AKT, Raf/MEKK/ERK1/2, NF-κB, Bcl-2, Bax,
Bad, or surviving [23, 80–82]. West et al. demonstrated
inhibition of apoptosis and promotion of proliferation in
human bronchial epithelium cells by NNK are induced
via activation of α3/α4 nAChR followed by upregulation
of AKT, mitogen-activated protein kinase (MAPK), and
PKC pathways [48]. Similar results are also observed by
Xu and coworkers showing that both AKT and survivin
pathways are involved in anticisplatin-induced apoptosis
by nicotine [79]. Indeed, drug-induced enhancements of
p53 and p21 expressions are shown to be suppressed
by nicotine. This anti-apoptotic mechanism is mediated
through α3n A C h R[ 83]. Our recent study also indicated
that long-term nicotine treatment activated α4/β2n A C h R
and β-AR leading to reduction of apoptosis induced by
cisplatin or paclitaxol [57]. Consistently, Zhao et al. also
reported that nicotine induced up-regulation of Mcl-1
phosphorylation though ERK1/2 via β-AR activation with
increased chemoresistance (anti-apoptosis) of human lung
cancer cells [84]. Other investigators also indicate that NNK
can prevent cell apoptosis by modulating the anti-apoptotic
Bcl-2 and c-Myc proteins [23]. Heme oxygenase-1 (HO-
1) is a protein induced during oxidative stress. It is found
to be associated with cellular proliferation and is elevated
during the developments of certain malignant tumors such
as gastric and thyroid cancers [11–13]. Comparing the
HO-1 in lung tissues of smokers and nonsmokers, Li et
al. noticed that the expression of HO-1 is signiﬁcantly
increased in both tumor and nontumor tissues of smokers.
These studies further revealed that NNK or its metabolites
probably induce oxidative stress in lung tissues with ele-
vation on stimulates the expression of HO-1. Such event
is through ERK and NF-κB activation and Bad phospho-
rylation induction leading to eventual apoptosis inhibition
[11, 85].
Cell proliferation and apoptosis can also be modulated
by the peroxisome proliferator-activated receptors (PPARs).
PPARs are members of nuclear hormone receptor super-
family of ligand-dependent transcription factors. The major
PPAR isoforms are α, β/δ,a n dγ [86]. PPARβ/δ is expressed
in most tissues and has been reported to be associated with
cancer growths, especially those in liver, colon, breast and
lungs [87–89]. Sun et al. reported a novel mechanism that
nicotine increases PPARβ/δ expression through α7n A C h R
follow by PI3K/mTOR activation leading to enhanced lung
tumor cells proliferation [90]. In contrast to PPARβ/δ,a c t i -
vation ofPPARγ byitsligands inducesapoptosisand inhibits
cell proliferation [91]. Thus, an intact PPARγ levels or its
activation is needed to reduce cancer risk (anti-apoptosis
and cell proliferation). Interestingly enough, activation of
PPARγ is found to be defective in lung cancers [92].
Furthermore, a signiﬁcant reduction in the transcriptional
activity of PPARγ and its endogenous ligands, including
15-S-Hydroxyeicosatertraenoic acid (15(S)-HETE) and 3-
S-hydroxyocatadecadienoic acid (13(S)-HODE), are found
reduced in lung tissues of NNK-treated mice. Indeed, lung
tumors developed in these mice later. Yuan et al. further
suggested that the reduction of 15(S)-HETE and 13(S)-
HODE may enable lung cells to be more resistant to
apoptosis by NNK and facilitate tumor development in the
animals [93].
In contrast to nicotine or NNK, PAHs induce either
apoptosis or antiapoptosis in mammalian cells [94, 95]. For
instance, BaP is known to induce signaling through IGFR
and increases cell survival through PI3Kactivation in human
mammary epithelial cells [68]. Solhaug et al. reported that
both AKT and ERK1/2 act as anti-apoptosis signals leading
to Bad phosphorylation. However, BaP can also induce
apoptosis through p53 and p21 signaling in the same model
[96]. The results suggest that BaP is capable in stimulating
both apoptosis and anti-apoptosis signals. Teranishi et al.
reportedthatlight-irradiatedBaP(LBaP)inhibitedapoptosis
through production of ROS from degraded BaP [97]. This
anti-apoptotic signal induced by BaP in combination with
DNA damage would increase the possibility of cell survival
and producing mutations. Thus, while the apoptotic signal
of BaP induces cell death (cytotoxicity), the anti-apoptotic
signals ofBaP play an important role in cell proliferationand
carcinogenesis. The precise factors inﬂuencing either apop-
totic or anti-apoptotic outcome are still unclear. The anti-
apoptosis mechanisms induced by components of cigarette
smoke are obviously quitecomplex.It isevidentthat evading
apoptosis plays a critical role in cigarette smoke-induced
tumorigenesisandchemoresistance.Furtherexplorationsare
very much needed. New understandings on the molecular
target regulating the apoptotic and anti-apoptosis machiner-
ies by cigarette smoke could provide novel strategies fordrug
development with substantial therapeutic beneﬁts.
2.4. Eﬀects of Cigarette Smoke on Replicative Lifespan. When
a cell populationhasprogressed through a certain number of
doublings (replications), they would normally stop growing
and enter into a process called “senescence”. Tumor cells,
however, appeared to have limitless replicative potentials
(immortalization) during tumor progression [29]. Telom-
eres, which deﬁnetheendsegmentsofchromosomes, consist
of short, tandemly repeated DNA sequences (TTAGGG)n
together with associated proteins. They represent important
devices in controlling cell divisions and proliferations. Small
amount of these end DNA sequences may be lost during
each cell cycle as a result of incomplete DNA replication.
However, de novo additions of TTAGGG repeats by the
enzyme telomerase may compensate for this loss [98]. Thus,
telomerase plays an important role in the maintenance6 Journal of Oncology
of the telomere ends in normal cells. Ectopic expression of
telomerase would immortalize the cells.
By using human tissue samples, Yim et al. reported that
there are diﬀerent distributions of the telomerase activity
between smokers or ever-smokers and non-smoker. A strong
correlation between telomerase activity and the number of
packs years smoked can be established among these subjects
indicating that there is an association between tobacco
exposure and telomerase activity in the human bronchial
epithelium. Increased telomerase activity would extend the
“lifespan” of cells and put these cells to be at higher risks for
malignant transformation and carcinogenesis [99]. Similar
ﬁnding is reported by Targowski et al. that extensiveness
of tobacco smoking correlated positively with increases in
telomerase activity in tumor cells from patients with non
s m a l lc e l lc a r c i n o m ao ft h el u n g s[ 100]. All these studies
point to the fact that enhancement of the telomerase activity
by cigarette smoke certainly underlies the cancer promotion
potentials of cigarette smoke. However, which components
in cigarette smoke altered telomerase activity are still not
known. Further study in this aspect is very much needed.
2.5. Eﬀects of Cigarette Smoke on Mobilization of Cellular
Resources. Tumorigenesis requires adequate ability for pro-
tein synthesis and theenergy for activating signaling. Indeed,
there are indications that certain protein synthesis and mito-
chondria play central roles in neoplastic transformation.
It is well known that mTOR and MAP kinase signaling
pathways modulate the phosphorylation of transcriptional
factors, stability of mRNAs, and protein synthesis [101].
Jin et al. reported that both nicotine and its metabolite
NNK can induce survivin mRNA expression through AKT-
mTOR and mediated de novo synthesis of survivin protein in
normal lung epithelial cell HBE cells. This induced survivin
expression has been claimed to play a role in the malignant
transformation of HBE cells by stimulating the survival
pathways [102].
Cigarette smoke may damage respiratory chain function
in mitochondria enhancing oxidative stress leading to mito-
chondria dysfunction [103, 104]. It has also been reported
that nicotine exposure resulted in reduced pancreatic mito-
chondrial enzyme activity, degranulation of beta cells, ele-
vated islet oxidative stress, and impaired glucose stimulated
insulin secretion in rats [105]. Continued exposure to ROS
and free radicals from such “mitochondrial stress” may
lead to mitochondria DNA (mtDNA) mutation which may
play an important role in carcinogenesis [106]. Analyzing
clinical samples, Tan et al. demonstrated mtDNA mutation
in buccalcellsofsmokers[107].Petros etal. also showed that
tumor cells with mtDNA mutations grow faster then cells
without mitochondrial mutation[108]. Hence, it is apparent
that cigarette smoke would induce oxidative damage to the
mtDNA leading to more aggressive tumor growths. Impact
of cigarette smoke or its components on mitochondrial
dysfunction needs further exploration.
Step 3 (Cancer Progression). The “malignancy” of a tumor is
usually evaluated by its ability in invasion and metastasis as
well as in the associated angiogenesis. There are ample evi-
dence which indicate that cigarette smoke participates in the
processes of angiogenesis, invasion, and tumor metastasis.
These phenomena are presented and discussed below.
3.Effectsof CigaretteSmokeon
Sustained Angiogenesis
Angiogenesis, the development of new blood vessels from
endothelial cells (ECs), is a critical event which allows
t h ec a n c e rc e l l st or e c e i v ea d e q u a t en u t r i e n t sa n do x y g e n .
Angiogenesis involves mature vascular changes, including
detachment of pericytes, degradation ofextracellular matrix,
endothelial cells remodeling, proliferation, migration, and
formation of new endothelial cells into tubular structures
[109]. Survival and proliferation of vascular endothelial
cells are often stimulated by tumor-derived mitogens, and
vice versa. Tumor cells are known to activate angiogene-
sis by changing the balance of angiogenic inducers such
as VEGF (vascular endothelial growth factor) and bFGF
(basic ﬁbroblast growth factor), and by countervailing
inhibitors such as thrombospondin-1 [29]. VEGF promotes
angiogenesis and lymphangiogenesis in tumors, providing
routes for dissemination. It has been shown that nicotine
can induce angiogenesis both in vitro and in vivo and
contributes to the growth of tumors [30, 110]. Similar
to the FGF, nicotine is found to have the ability to pro-
mote migration, proliferation, tube formation and nitric
oxide (NO) production of endothelial cells [111]. NO is
a well-known vasodilator and angiogenesis mediator, and
nicotine has been reported to enhance the expression of
endothelial nitric oxide synthetase and promote NO release
[110].
Nicotineisalsofoundtoinduceexpression ofendothelial
growth factors such as VEGF, bFGF, PDGF, TGF-α,andT GF -
β in endothelial cells and smooth muscle cells [112, 113].
Enhanced bFGF release and increases in metalloproteinase
expression with degradation of ECM have been demon-
strated with nicotine [114, 115]. Moreover, nicotine is found
to induce secretion of prostacyclin which is a vasodilating
molecule associated with endothelial cell proliferation, sur-
vival and migration [116]. These eﬀects are believed to be
associated with cigarette smoke-induced hyperplasia of the
intima in the blood vessels and other vascular wall lesions
[115].
Tumor angiogenesis can also be modulated by the
nAChR [117]. α7 nAChR is important in both physiological
and pathological angiogenesis [110, 118]. α7n A C h Ri n
endothelial cells needs to be sensitized or activated by
hypoxia or ischemia in order to induce angiogenesis [110].
Indeed, speciﬁc antagonist of the α7n A C h R( α-bunga-
ratoxin) is shown to inhibit nicotine-induced angiogene-
sis (new vascular tube formation from endothelial cells)
[25, 114]. Interestingly enough, it is apparent that the AKT
pathway is found to be not involved in either angiogenesis
or VEGF release induced by nicotine [25]. In contrast,
Heeschen et al. suggested that inhibition of ERK1/2, p38
MAPK, and PI3K/AKT can completely block and preventJournal of Oncology 7
endothelial tubule formation induced by nicotine-triggered
α7 nAChR activation [110]. Consistent with Heeschen’s
study, Zhang and coworkers reported that nicotine appar-
ently increases angiogenesis and invasion by activating PKC,
PI3K/AKT, ERK1/2, mTOR, and Src in human NSCLC
[119]. Excellent reviews on angiogenesis induced by nicotine
were recently published [120, 121] and will not be further
discussed here.
Interaction between nAChR and the growth factor-
mediated angiogenesis occurs at signaling and transcription
levels.Nicotine-inducedexpression ofVEGFhasbeenshown
to be regulated by EGFR transactivation and via the ERK1/2
pathway in smooth muscle cells [122]. Phosphorylation of
the VEGF receptor KDR by nicotine activates VEGF and
increases its activity [112]. Additionally, nicotine can also
upregulate the expression of VEGF receptor VEGFR2 during
angiogenesis in certain cancer cells [123]. Recent study
further indicated that nicotine can synergistically promote
the proangiogenic eﬀect of estradiol in nonsmall lung cancer
[124]. Induction of angiogenesis in colon cancer by nicotine
via β-AR followed by arachidonic acid pathway has also been
reported [32, 125].
In sum, α7 nAChRsubtypehasbeen linkedto angiogenic
process induced by nicotine leading to tumor vascularity,
inﬂammation, and ischemia. Nevertheless, whether nicotine
or NNK acts speciﬁcally via nAChR or β-AR receptors or
both or whether it is controlled in a cell-speciﬁc manner
needs further study. Other components present in cigarette
smoke that may also contribute to angiogenesis remain to
be identiﬁed. The signiﬁcant role of nAChR in various
pathogenic angiogenesis is still largely unknown. This infor-
mation would be critical for the development of new anti-
angiogenic therapies. Several excellent reviews on the roles
of nicotine and nAChR in angiogenesis exist [117, 120, 121,




The ability of invasion and metastasis allows cancer cells
to escape from the primary tumor mass to new terrains
in the body. Metastasis is the ﬁnal and most devastating
consequence in malignancy. The processes of invasion and
metastasis are exceeding complex. The genetic and bio-
chemical determinants as well as the molecular mechanisms
involved are still poorly understood. Many evidence indicate
that cigarette smoking not only increases proliferation of
cancer cells but also promotes metastasis [127]. Clinical
and epidemiological studies suggest that smokers have more
rapidly progressing tumors and cancer metastasis than non-
smokers [128]. These processes are now known to be depen-
dentoncellularandstromalinteractionsandonextracellular
matrix degradation. E-cadherin is a cell-to-cell interaction
molecule expressed on epithelial cells. A loss of E-cadherin is
seen in epithelial to mesenchymal transition (EMT), which
is a major pathologic event in cancer metastasis. Chronic
treatment of nicotine downregulated the expression of ECM
proteins such as E-cadherin and β-catenin with concomitant
increases of ﬁbronectin and vimentin in lung cancer cells
[129]. Wei et al. also indicated that NNK enhanced colon
cancer cell migration with downregulation of E-cadherin.
This author also found that the expressions of Snail and
ZEB1, 2 major transcription repressors of E-cadherin, were
also induced by NNK in colon cancer cell cultures [44].
Contactin-1 is a glycophosphotidylinositol (GP)-anchored
adhesion molecule. Its upregulation is signiﬁcantly linked
with tumor progression, metastasis and poor prognosis in
lung cancer patients [130]. It has been shown that NNK can
upregulate contactin-1 via α7 nAChR/ERK activation and
enhances invasiveness of lung cancer cells [131].
Thesecondgeneralmediatorsforinvasionandmetastasis
are the extracellular proteases [29]. Breakdown of the extra-
cellular matrix (ECM) through a family of enzyme called
matrix metalloproteinases (MMPs) is needed for tumor cells
to invade adjacent tissue and to metastasize. Zong et al.
reported that nicotine enhanced the invasiveness of esophag-
eal squamous carcinoma cells (TE-13) by up-regulating the
expressions and activity of MMP-2, and COX-2 [132]. Nico-
tine is found to enhance the activity of MMP-2, and MMP-
9 as well as activation of plasminogen activators in a COX-
2 and VEGF-dependent manner [123]. Osteopontin (OPN)
is a proinﬂammatory and pro-metastatic protein. It can be
upregulated by nicotine.It servesasa goodmarker forPDAC
(pancreatic ductal adenocarcinoma) metastasis especially in
cigarettesmokingpopulation[133].Inarecentinvestigation,
Lazar et al. demonstrated that nicotine contributes to PDAC
metastasis through the induction of MMP-9 and VEGF
mediated by OPN [134].
PAHs, including BaP, are also found to play a role in
the promotion of cancer metastasis. Through augmented
COX-2 expression and PGE2 production via activated AhR
pathway, BaP induces breast cancer cell invasions [135]. BaP
and PAHs mixture has also been demonstrated to induce
cancer cell invasions and metastasis through upregulating
the expressions of MMPs, proteinase-activated receptor-2,
ﬁbronectin, migration stimulating factor, and Bcl-2 protein
in lung adenocarcinoma [136]. The importance of FGF-9
and its up-regulation by BaP in lung cancer invasion and
metastasis has been proposed. Indeed, recent study by Ueng
et al. [137] demonstrated that BaP increases the invasive
potential of lung cancer cells in vitro.S u c hp r o c e s si n v o l v e s
the up-regulation of FGF-9 mRNA expression via the p38
and ERK1/2 pathways [137].
During metastasis, the cancer cells co-opt signals that
control leukocyte traﬃcking and chemokines-mediated cell
migration [138]. Among these chemokines, CXCR4 and its
natural ligand CXCL12 serve as key mediators for tumor
migration and metastasis [139]. Nicotine has been shown
to increase the expressions of several CXC chemokines
r e c e p t o r ss u c ha sC X C R 2 ,C X C R 3 ,a n dC X C R 4a sw e l la s
CCL12 in SCLC cells [140] suggesting the nicotine would
stimulate cancer cell migration and eventual metastasis.
Although epidemiology studies have long demonstrated
the relationship between smoking and cancer metastasis, the
molecular mechanisms of metastasis inﬂuenced by cigarette
smoke or its components remain very limited. Further
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Figure 1: Diagrammatic models summarizing simpliﬁed molecular mechanisms of genotoxic and non-genotoxic modes of action in
carcinogenesis by cigarette smoke. (a) Nitrosamines and PAHs are carcinogens, inducing genotoxic eﬀects leading to cancer initiation.
(b) Non-genotoxic (epigenic) eﬀects of cigarette smoke components (nicotine, nitrosamines, and PAHs) in cancer promotion and
progression. Activation of nAChR, β-AR, or AhR, followed by neurotransmitters release, activation of signaling pathways (PKA, 5-LOX,
Stat3 and PPARβ/δ), and increased the expression of transcriptional factors (JUN, FOS, MYC, and CREB) regulate cancer promotion by
cigarette smoke. PKC, PI3K/AKT, ERK, and COX-2 signaling pathways downstream of receptors play important roles in both promotion
and progression stages. p38, Src, VEGF, and NO releasing involve in enhancement of cancer progression by cigarette smoke.
5.Summary,ConclusiveRemarks,
and FuturePerspectives
In this paper, we have reviewed the recent investigations
concerning cigarette smoke and cancer development, pro-
motion and progression. While chemicals with carcinogenic
potentials in cigarette smoke are many (over 62), most
research eﬀorts have been devoted to three components of
cigarette smoke: nicotine, NNK, and PAHs. While PAHs are
common chemicals in the environment, nicotine and NNK
are considered to be tobacco speciﬁc. These three important
components of cigarette smoke, especially nicotine and
NNK, therefore, are targeted as the major compounds of
focus in this review. Many previous reviews have devoted
to the interrelationship between cigarette smoke and lung
carcinogenesis or the genotoxicity of cigarette smoke or
its components. In this review, we are focused on the
mechanistic information on tumorigenesis, especially those
involving epigenetic or non-gentoxic eﬀects. Aside from
lung cancer, other tobacco-related cancers are also discussed.
It is our hope that this review will summarize the vast
information cumulatedintheliteratureand providevaluable
reference resource for those who are interested in tobacco-
related carcinogenesis.
The overall mechanisms on carcinogenesis cancer pro-
motion and progression are complex involving many molec-
ular targets which include receptors, cell cycle regulators,
mitogen-activated protein kinases, apoptosis mediators,
angiogenic factors, and invasion, and metastasis mediators.
Among the receptors, nAChR, β-AR, and AhR probably are
the most important and have the closest association with
cigarette smoke-induced carcinogenesis. Overexpression or
activation of these receptors may result in the release of
neurotransmitters and growth factors that participate in
apoptosis inhibition, cell proliferation, angiogenesis, cancer
cell invasion and metastasis. It should be noted that the
importance of nAChR in cancer may be cell-type-dependent
or speciﬁc and their sensitivity and expression can be
also be modiﬁed by various environmental factors such as
insecticide organophosphates [141].
As shown in Figure 1, signaling pathways, PI3K/AKT,
Stat3, and ERK1/2 play important roles in the carcinogenesis
processes. They are also common paths aﬀected by the
cigarette smoke components, including nicotine, NNK, andJournal of Oncology 9
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pathways are involved in both promotion and progression
stages by cigarette smoke. It is suggested that these molecules
could be utilized the potential targets for future develop-
m e n t si nc a n c e rd i a g n o s e so rt h e r a p i e s .
Avoidance of cigarette smoke remains to be the best
way of prevention for cigarette-related cancer. However, in
view that tobacco smoke is legalized and smokers are still
abundant, understanding on the health impacts by tobacco
smoking still constitutes important public health concern.
Understanding the disease process and the mechanisms
involved is the ﬁrst step to solution. The emerging under-
standing on the molecular mechanisms in the development
and progression of caners induced by cigarette smoke
provides novel inspirations and approaches for potential
measures on early diagnosis, reduction in progression and
metastasis, and therapy of cancers. Many dietary supple-
ments,foods, orherbalmedicinesmightsigniﬁcantly attenu-
ate the proliferative eﬀectsbycigarette smoke. They may also
enhance antigrowth signals to reduce cancer growth. From
our own experience, the natural compound pterostilbene
could induce apoptosis and autophagy in chemoresistant
bladder cancer cells derived from nicotine exposure [142].
Future research on natural compounds may help to provide
additional novel chemopreventive or chemotherapeutic pos-
sibilities in reducing cancer risks or other health impacts of
cigarette smoke. This area of research is still weak and should
be explored.
This review has also discussed the various molecular
mechanisms and paths involved in carcinogenesis induced
by cigarette smoke. However, there are still many mysteries
in the carcinogenic process by cigarette smoke. Several
recommendations can be oﬀered for future research needs.
(1) In the past, most research eﬀorts were focused on the
proliferative and antiapoptosis mechanisms induced
by cigarette smoking. As tumors are the results of
multiple and interactive genetic abnormalities, study
of cancers induced by cigarette smoke should assess
more than one or two acquired alterations or paths.
Explorations of other “paths” or mechanism other
than those “popular” ones are needed.
(2) Those molecular pathways which are signiﬁcantly
activated by cigarette smoke are probably the
most important ones involved in cigarette smoke-
induced tumorigenesis. These pathways include
nAChR signaling (such as α7n A C h R ,α9n A C h R ,o r
α4/β2n A C h R ) ,β-AR signaling, PI3K/AKTsignaling,
ERK1/2 signaling, Stat3 signaling, VEGF, and MMPs
pathways, and so on. Targeting to modulate these
pathways via dietary factors or therapeutic drugs
may reduce cigarette smoking induced tumorigenesis
signiﬁcantly. Studies on the non-genotoxic (epige-
netic) eﬀects of cigarette smoke components are few
and need more eﬀorts. The epigenetic eﬀects of
cigarette component must be evaluated to include
both upstream and downstream pathways.
( 3 )C a r c i n o g e n e s i si so f t e ns p e c i e so rc e l l - t y p es p e c i ﬁ c
and can be inﬂuenced by many factors or cofactors.
Proper study of carcinogenicity requires consider-
ation of these diﬀerent variables. The same factor
which is highly oncogenic to certain cell type or indi-
viduals may not be oncogenic to others. Moreover,
some cell type may become susceptible to a “carcino-
gen” only in the presence of certain factor(s), co-
factor(s), genetic predisposition, or immune depres-
sion. Identiﬁcation of such inﬂuencing factors will be
important. Speciﬁc “mechanism” for carcinogenesis
for the same “carcinogen” may also vary in diﬀerent
tissues. Information obtained will be helpful for
future cancer prevention, diagnosis and treatment.
(4) Synergisticinteraction betweencigarettesmoke com-
ponents and other environmental toxicants or car-
cinogens, such as arsenic or dioxin, on cancer devel-
opment has been demonstrated both epidemiologi-
cally and in animal studies [143–145]. Traditionally,
most past investigations focused only on “single”
compound or one cigarette smoke component. The
synergistic interaction between otherwise “safe” level
of environmental chemical and low level of cigarette
smoke or its component (via either active or second-
hand smoking) for carcinogenesis raised novel public
health concerns and challenging questions. This area
of research certainly deserves future attentions and
eﬀorts.
In conclusion, we have provided an overview on the
major concepts and insights on the molecular mechanisms
involved in cigarette smoke-induced cancers. It is hoped that
these mechanistic insights can be translated into practical
applications for the prevention and treatment of cigarette
smoke-related cancers. We have also oﬀered several recom-
mendations for future research. We also hope that these
suggestions will be helpful to those who are interested in this
area of cancer research.
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